A Kansas district court judge has dismissed motions by Mylan, Pfizer, and others to dismiss class action complaints accusing them of RICO Act violations, specifically, their activities aimed at monopolizing the market for emergency allergy med EpiPen (epinephrine).
The lawsuit alleges Pfizer and Mylan engaged in “an illegal scheme to monopolize the market” for epinephrine auto-injectors. The scheme allegedly involved raising the price of EpiPen and then using the higher margins to offer larger rebates and discounts to pharmacy benefit managers (PBMs) in exchange for better or exclusive formulary positions.
Plaintiffs also claimed the companies abused patent law and regulatory processes to delay competitor products from coming to market. For example, they argue the defendants entered an “unlawful settlement agreement” in 2012 by which Teva postponed the launch of its EpiPen generic until mid-2015. Yet six months before that launch time, Mylan filed a Food and Drug Administration Citizen Petition, calling into question whether the copycat product was equivalent to EpiPen and thereby further stalling its market entry.
The suit in the US District Court for the District of Kansas will continue despite Mylan and Pfizer’s protests. While Judge Daniel Crabtree dismissed several of the plaintiffs’ claims, he found there was adequate support behind the rest.
Full Content: Biopharma Dive
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ Antitrust Chief Gail Slater Assembles Veteran Team for Key Cases
Mar 16, 2025 by
CPI
UK Demands Access to Apple’s Encrypted Cloud Data, Spark Legal and Privacy Battle
Mar 16, 2025 by
CPI
Turkey Probes Netflix, Disney+, and Amazon Over Anti-Competitive Practices
Mar 16, 2025 by
CPI
Elon Musk and OpenAI Agree to Accelerate Trial Amidst Legal Battle Over AI’s For-Profit Shift
Mar 16, 2025 by
CPI
AI in Markets: A Double-Edged Sword for Competition, Says CCI Chief
Mar 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li